Vyome’s lead candidate is VB 1953, a first-in-class topical bactericidal antibiotic being developed to treat antibiotic-resistant acne and reduce inflammation. The company planned to initiate a US phase 2b clinical trial of VB 1953 in Q1 2019 and is advancing the molecule through phase 2 studies for moderate to severe acne. Vyome also has a pipeline of preclinical new chemical entities based on its patented Dual Action Rational Therapeutics (DARTs) technology. The company has developed antifungal products from its Molecular Replacement Therapeutics (MRT™) platform and has out-licensed marketing rights for that platform to a large specialty pharmaceutical company. Vyome said the addressable US opportunity for antibiotic-resistant P. acnes could be roughly $2B. The company underwent a corporate restructuring to establish operations and headquarters in the United States. Vyome Biosciences is a clinical-stage specialty biopharmaceutical company based in New Delhi developing novel drugs for skin diseases caused by resistant microbes. Its lead program is VB 1953 for the treatment of antibiotic-resistant acne, which recently received FDA acceptance. The company also develops proprietary candidates targeting opportunistic pathogens and antifungal indications in dermatology. Vyome intends to use the Series C proceeds to advance the clinical development of VB 1953 while continuing work on other pipeline products. Leadership includes Co-Founder & CEO Venkateswarlu Nelabhotla (N. Venkat) and Co-Founder Dr. Shiladitya Sengupta. The company raised $14M in Series C financing to fund these clinical and development activities. Vyome Biosciences focuses on developing therapeutics for hard-to-treat and refractory dermatology diseases. It has completed clinical research on two products and has two lead compounds in preclinical stages of a USFDA program. The company is building a pipeline that includes molecules to kill dandruff-causing fungus and new antibiotics targeting resistant acne-causing bacteria, and it has developed a robust global patent portfolio. Vyome recently completed clinical studies on VB001 and VB2421 for mild to moderate dandruff. Management says the financing will fund USFDA filings and Phase 1 and Phase 2 clinical research, plus further development and commercialization of its Rx and OTC pipeline. The company was founded in August 2010 and is based in Delhi. Vyome Biosciences develops dermatology and skin-care therapeutics, with lead programs targeting dandruff and acne. The company has filed multiple Indian and global patents on its platform technologies. Vyome plans to use the new funding to support clinical development of its lead anti-dandruff products and to accelerate pre-clinical development of its anti-acne candidates. Its founders include Rajesh Gokhale, Shiladitya Sengupta, and Rajeev Mantri, and the company was set up in August 2010. Vyome received seed funding from Navam Capital prior to this round. Leadership has expressed a vision to launch global products originating from India and to address the large global dermatology market. Vyome Biosciences is a new venture focused on dermatology and skin care. It will develop research-based pharmaceutical solutions for anti-fungal indications, chronic wound healing, and pigmentary disorders such as vitiligo. The company is targeting the global dermatology and wound care market, which the article estimates at over $15 billion. Vyome has received an early-stage investment of $1 million from Navam Capital. The description in the article emphasizes research-driven therapeutic development within dermatology rather than consumer skincare products.

Total raised

$48M

Funding rounds

5

Latest round

Series D

Latest activity

Jan 2019